Poveda E - Search Results

1

Raltegravir and etravirine are active against HIV type 1 group O.

Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V. Briz V, et al. Among authors: poveda e. AIDS Res Hum Retroviruses. 2009 Feb;25(2):225-7. doi: 10.1089/aid.2008.0222. AIDS Res Hum Retroviruses. 2009. PMID: 19239363

2

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

Poveda E, Rodés B, Toro C, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V. Poveda E, et al. AIDS. 2002 Sep 27;16(14):1959-61. doi: 10.1097/00002030-200209270-00014. AIDS. 2002. PMID: 12351957 No abstract available.

3

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Rodés B, Poveda E, Soriano V. Rodés B, et al. Among authors: poveda e. J Clin Microbiol. 2002 Nov;40(11):4313-6. doi: 10.1128/JCM.40.11.4313-4316.2002. J Clin Microbiol. 2002. PMID: 12409418 Free PMC article.

4

Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor.

Toro C, Rodés B, Poveda E, Soriano V. Toro C, et al. Among authors: poveda e. Transplantation. 2003 Jan 15;75(1):102-4. doi: 10.1097/00007890-200301150-00019. Transplantation. 2003. PMID: 12544880

5

Transmission of HIV type 1 through blood transfusion from an antibody-negative/p24 antigen-negative donor.

Toro C, Rodés B, Colino F, del Valle Flores M, Poveda E, de Mendoza C, Téllez MJ, Soriano V. Toro C, et al. Among authors: poveda e. AIDS Res Hum Retroviruses. 2003 Jun;19(6):447-8. doi: 10.1089/088922203766774478. AIDS Res Hum Retroviruses. 2003. PMID: 12882652

6

Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?

Poveda E, de Mendoza C, Cuesta M, Toro C, Rodés B, Soriano V. Poveda E, et al. AIDS Patient Care STDS. 2003 Jul;17(7):321-4. doi: 10.1089/108729103322231259. AIDS Patient Care STDS. 2003. PMID: 12952733

7

Are fusion inhibitors active against all HIV variants?

Poveda E, Rodes B, Toro C, Soriano V. Poveda E, et al. AIDS Res Hum Retroviruses. 2004 Mar;20(3):347-8. doi: 10.1089/088922204322996590. AIDS Res Hum Retroviruses. 2004. PMID: 15117459

8

Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection.

Rodés B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, Jimenez V, Wrin T, Bassani S, Soriano V. Rodés B, et al. Among authors: poveda e. AIDS. 2004 May 21;18(8):1109-16. doi: 10.1097/00002030-200405210-00004. AIDS. 2004. PMID: 15166526

9

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V. Poveda E, et al. J Med Virol. 2004 Sep;74(1):21-8. doi: 10.1002/jmv.20141. J Med Virol. 2004. PMID: 15258964 Clinical Trial.

10

Enfuvirtide is active against HIV type 1 group O.

Poveda E, Barreiro P, Rodés B, Soriano V. Poveda E, et al. AIDS Res Hum Retroviruses. 2005 Jun;21(6):583-5. doi: 10.1089/aid.2005.21.583. AIDS Res Hum Retroviruses. 2005. PMID: 15989465

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters